


**In the Claims**

**Listing of claims**

1. (Original) A compound of formula (I):



or a salt or solvate thereof, wherein:


R<sup>1</sup> is -<sup>11</sup>CH<sub>2</sub>R<sup>5</sup> or [<sup>18</sup>F]-C<sub>1-4</sub> fluoroalkyl wherein R<sup>5</sup> is hydrogen or C<sub>1-4</sub> alkyl;

R<sup>2</sup> is hydrogen or C<sub>1-4</sub> alkyl;

R<sup>3</sup> is halo; and


R<sup>4</sup> is halo, C<sub>1-4</sub> alkylthio, or C<sub>1-4</sub> alkyl.

2. (Original) A compound according to claim 1 of formula (Ia) :



or a salt or solvate thereof, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are as defined in claim 1.

3. (Currently amended) A compound according to claim 1 or 2 of formula (Ib):




or a salt or solvate thereof, wherein:

R<sup>4</sup> is C<sub>1-4</sub> alkylthio;

R<sup>1</sup> is either -<sup>11</sup>CH<sub>3</sub>, -<sup>11</sup>CH<sub>2</sub>CH<sub>3</sub>, or -<sup>11</sup>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> or R<sup>1</sup> is -CH<sub>2</sub><sup>18</sup>F, -CH<sub>2</sub>CH<sub>2</sub><sup>18</sup>F, or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub><sup>18</sup>F.

4. (Original) A compound of formula (Ic):



or a salt or solvate thereof, wherein:

R<sup>1c</sup> is C<sub>1-4</sub> alkyl or C<sub>1-4</sub> haloalkyl;

R<sup>2c</sup> is hydrogen or C<sub>1-4</sub> alkyl;

R<sup>3c</sup> is radioiodine (suitably <sup>123</sup>I, <sup>124</sup>I, <sup>125</sup>I, or <sup>131</sup>I); and

R<sup>4c</sup> is halo, C<sub>1-4</sub> alkylthio, or C<sub>1-4</sub> alkyl.

5. (Currently amended) A compound according to ~~any one of claims 1 to 3~~ claim 1,

selected from:

(N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)-N'-[N-methyl-<sup>11</sup>C]-methylguanidine; and

(N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)-N'-[<sup>18</sup>F]-fluoromethylguanidine;

or a salt or solvate thereof.

6. (Currently amended) A compound according to ~~any one of claims 1 to 5~~ claim 1, for use in an *in vivo* diagnostic or imaging method such as PET.

7. (Currently amended) Use of a compound according to ~~any one of claims 1 to 5~~ claim 1, in the manufacture of a radiopharmaceutical for the *in vivo* diagnosis or imaging of an NMDA-mediated disease.

8. (Currently amended) A method for the *in vivo* diagnosis or imaging of NMDA-mediated disease in a subject, preferably a human, comprising administration of a compound according to ~~any one of claims 1 to 5~~ claim 1.